Benefit-Risk Of arterial THrombotic prEvention with Rivaroxaban for atrial fibrillation in daily clinical practice. A French cohort within the nationwide claims and hospital database (BROTHER).

First published 02/08/2016

Last updated 23/04/2024

EU PAS number:

EUPAS14567

Study

Finalised

Documents

Study protocol

Initial protocol

BROTHER_ENCePP_Protocol_V1.0_20181203

English (7.17 MB - PDF)View document

Study results

BROTHER_Study_report_1-year_follow-up_V3.0_Clean_20181120

English (3.88 MB - PDF)View document

BROTHER_Study_report_2-year_follow-up_V1.0clean_20181116

English (4.5 MB - PDF)View document

Study report

Other information

Publications

Study publications

Secondary tabs